These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15466129)

  • 61. QuilliChew ER--extended-release chewable methylphenidate tablets.
    Med Lett Drugs Ther; 2016 May; 58(1495):68-9. PubMed ID: 27192619
    [No Abstract]   [Full Text] [Related]  

  • 62. Splitting the self: the not-so-subtle consequences of medicating boys for ADHD.
    White GB
    Am J Bioeth; 2005; 5(3):57-9. PubMed ID: 16006364
    [No Abstract]   [Full Text] [Related]  

  • 63. Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.
    Ermer JC; Adeyi BA; Pucci ML
    CNS Drugs; 2010 Dec; 24(12):1009-25. PubMed ID: 21090837
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sustained-release methylphenidate.
    Med Lett Drugs Ther; 1984 Oct; 26(673):97-8. PubMed ID: 6384753
    [No Abstract]   [Full Text] [Related]  

  • 65. More objective tools should be employed to objectify the therapeutic response.
    Yang R; Mao S; Li R; Zhao Z
    J Dev Behav Pediatr; 2010; 31(9):733. PubMed ID: 21057259
    [No Abstract]   [Full Text] [Related]  

  • 66. Acute generalized exanthematous pustulosis induced by methylphenidate: a new adverse effect.
    Heinzerling LM; Pichler W; Anliker MD
    Arch Dermatol; 2011 Jul; 147(7):872-3. PubMed ID: 21768498
    [No Abstract]   [Full Text] [Related]  

  • 67. Nasal Bleeding Probably Associated with Methylphenidate.
    Avcil S
    J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):924-925. PubMed ID: 29131668
    [No Abstract]   [Full Text] [Related]  

  • 68. Critical assessment of the methylphenidate transdermal system.
    Kowalik S; Minami H; Silva RR
    Drugs Today (Barc); 2007 Aug; 43(8):515-27. PubMed ID: 17925883
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of osmotic-release oral system methylphenidate on different domains of attention and executive functioning in children with attention-deficit-hyperactivity disorder.
    Alloway TP
    Dev Med Child Neurol; 2011 Sep; 53(9):780. PubMed ID: 21518347
    [No Abstract]   [Full Text] [Related]  

  • 70. Is it truly random?
    Markey P
    Aust Fam Physician; 1999 Jan; 28 Suppl 1():S48. PubMed ID: 9988931
    [No Abstract]   [Full Text] [Related]  

  • 71. A case report of Concerta misuse in a patient with comorbid substance use disorder and attention deficit hyperactivity disorder.
    Rizkallah E; Legault L; Pampoulova T; Lévesque S; Bélanger M; Stavro K; Chiasson JP; Potvin S
    Am J Addict; 2011; 20(5):478-9. PubMed ID: 21838849
    [No Abstract]   [Full Text] [Related]  

  • 72. [Two times daily to manage daily life].
    von Kieseritzky K
    MMW Fortschr Med; 2015 Mar; 157 Suppl 1():88. PubMed ID: 26012999
    [No Abstract]   [Full Text] [Related]  

  • 73. Treatment of attention deficit and borderline personality disorders with psychostimulants: case report.
    Hooberman D; Stern TA
    J Clin Psychiatry; 1984 Oct; 45(10):441-2. PubMed ID: 6480572
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Use of partial area under the curve metrics to assess bioequivalence of methylphenidate multiphasic modified release formulations.
    Stier EM; Davit BM; Chandaroy P; Chen ML; Fourie-Zirkelbach J; Jackson A; Kim S; Lionberger R; Mehta M; Uppoor RS; Wang Y; Yu L; Conner DP
    AAPS J; 2012 Dec; 14(4):925-6. PubMed ID: 22976173
    [No Abstract]   [Full Text] [Related]  

  • 75. Use of methylphenidate for attention deficit hyperactivity disorder.
    Lexchin J
    CMAJ; 1991 May; 144(10):1209-10. PubMed ID: 2025813
    [No Abstract]   [Full Text] [Related]  

  • 76. [Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guideline. Part 1: overview and recommendations].
    Banaschewski T; Coghill D; Santosh P; Zuddas A; Asherson P; Buitelaar J; Danckaerts M; Döpfner M; Faraone SV; Rothenberger A; Sergeant J; Steinhausen HC; Sonuga-Barke EJ; Taylor E
    Z Kinder Jugendpsychiatr Psychother; 2008 Mar; 36(2):81-94; quiz 94-5. PubMed ID: 18622938
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.
    Elbe D; Barr AM; Honer WG; Procyshyn RM
    J Psychiatry Neurosci; 2014 May; 39(3):E32-3. PubMed ID: 24758945
    [No Abstract]   [Full Text] [Related]  

  • 78. [Treatment with central nervous system stimulants].
    Zlotnik G
    Ugeskr Laeger; 2004 Mar; 166(10):925; author reply 925. PubMed ID: 15045741
    [No Abstract]   [Full Text] [Related]  

  • 79. Sixty seconds on . . . ADHD.
    Hawkes N
    BMJ; 2015 Nov; 351():h6294. PubMed ID: 26612410
    [No Abstract]   [Full Text] [Related]  

  • 80. Who is using the drugs I prescribe?
    Winkelaar PG
    Can Fam Physician; 2002 May; 48():883. PubMed ID: 12053632
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.